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The primary sequence of the N-terminal somatomedin
B (SMB) domain of native vitronectin contains 44 amino
acids, including a framework of four disulfide bonds
formed by 8 closely spaced cysteines in sequence patterns similar to those found in the cystine knot family of
proteins. The SMB domain of vitronectin was isolated by
digesting the protein with endoproteinase Glu-C and
purifying the N-terminal 1–55 peptide by reverse-phase
high performance liquid chromatography. Through a
combination of techniques, including stepwise reduction and alkylation at acidic pH, peptide mapping with
matrix-assisted laser desorption ionization mass spectrometry and NMR, the disulfide bonds contained in the
SMB domain have been determined to be Cys5:Cys9,
Cys19:Cys31, Cys21:Cys32, and Cys25:Cys39. This pattern of
disulfides differs from two other connectivities that
have been reported previously for recombinant forms of
the SMB domain expressed in Escherichia coli. This arrangement of disulfide bonds in the SMB domain from
native vitronectin forms a rigid core around the Cys19:
Cys31 and Cys21:Cys32 disulfides. A small positively
charged loop is created at the N terminus by the Cys5:
Cys9 cystine. The most prominent feature of this disulfide-bonding pattern is a loop between Cys25 and Cys39
similar to cystine-stabilized ␣-helical structures commonly observed in cystine knots. This ␣-helix has been
confirmed in the solution structure determined for this
domain using NMR (Mayasundari, A., Whittemore, N. A.,
Serpersu, E. H., and Peterson, C. B. (2004) J. Biol. Chem.
279, 29359 –29366). It confers function on the SMB domain, comprising the site for binding to plasminogen
activator inhibitor type-1 and the urokinase receptor.
Vitronectin is a large glycoprotein with wide ranging distribution and function. The hallmark feature of the vitronectin
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structure is a series of distinct functional domains that allow it
to interact both with itself and with a number of other ligands
in a variety of environments including the circulation, extracellular matrix, and platelets (1– 4). Of particular interest is
the N-terminal somatomedin B (SMB)1 domain of vitronectin.
This domain contains the high affinity binding site for the
serpin PAI-1. The interaction between PAI-1 and vitronectin is
important to the function of both proteins in thrombolysis, cell
adhesion, and pericellular proteolysis (1, 5–9).2 Equally important for the adhesive properties of vitronectin are binding sites
for cell-surface receptors, including integrins and uPAR, that
are housed within this small N-terminal domain (2, 10 –15).
Because it is known that the SMB domain provides a high
affinity binding site for PAI-1 and that this interaction stabilizes PAI-1 in its physiologically active form, the structure of
the SMB domain of vitronectin has been hotly pursued. Computational predictions for the structure of this domain using a
threading algorithm were challenging compared with other
domains from vitronectin (16), as there were no reported structures at the time for homologues of this small domain containing four disulfides. Nevertheless, there are over 100 homologues in the sequence data base, suggesting that this folding
motif has been conserved in evolution. Only recently have
three-dimensional structures describing the SMB domain become available from two different approaches. First, an x-ray
structure has been reported on a co-crystal of PAI-1 and a
recombinant form of the SMB domain expressed in Escherichia
coli (17). Subsequently, we completed the determination of a
solution structure for the SMB domain purified from circulating vitronectin that was isolated from human plasma (18).
Although the two structures differ in overall fold, they share a
common feature, a single ␣-helix that contains key amino acids
for PAI-1 binding. Not surprisingly, a recent report using NMR
on a recombinant SMB arrived at a similar structure to that
observed in the co-crystal with PAI-1 (19).
Key to understanding the structure of the SMB domain is
defining the correct disulfide connectivities of the eight cysteines that exist in vivo. The magnitude of the problem can be
appreciated by comparison with classic work on ribonuclease,
in which over 100 possibilities exist for unique disulfide-bonding patterns for 8 sulfhydryls, and improper oxidation of di1
The abbreviations used are: SMB, somatomedin B; PAI-1, plasminogen activator inhibitor-type 1; rSMB, recombinant somatomedin B;
uPAR, urokinase-type plasminogen activator receptor; TCEP, Tris(2carboxyethyl)phosphine; HPLC, high performance liquid chromatography; IAM, iodoacetamide; NEM, N-ethylmaleimide; CAM, carbamidomethyl; MALDI-MS, matrix-assisted laser desorption/ionization timeof-flight mass spectrometry; CSH, cystine-stabilized helix; DTT,
dithiothreitol; NOE, nuclear Overhauser effect.
2
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Peterson, submitted for publication.
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sulfides during refolding yields an ensemble of misfolded enzymes exhibiting less than 1% activity (20, 21). In terms of
primary sequence, the SMB region is similar to a growing class
of proteins known to form cystine knots (22–24). However,
unlike typical examples of the growth factor cystine knot or the
inhibitory cystine knot proteins, the SMB domain of vitronectin
has four disulfide bridges rather than the more familiar three
disulfide arrangement. In this respect, the SMB domain shares
sequence features with some members of cystine knot families
that block ion channels, have anti-microbial activity and the
bone morphogenic protein agonists (24 –27).
Previous efforts to understand the structure of the SMB domain and, specifically, to define the disulfide pairings in this
domain have relied upon recombinant surrogates for the native
protein (17, 19, 28). We chose to isolate the N terminus of
vitronectin from the native monomeric form of the protein purified from human plasma for the purposes of this study, to avoid
any potential pitfalls inherent in using a recombinant protein to
determine native structure. Analyses of several representatives
of the cystine knot family have shown that disulfide bonds may
be eliminated or misfolded compared with those found in the
native peptide, while retaining complete or nearly complete biological activity (29, 30). Thus, there is no reliable way to assure
that a peptide derived from a recombinant source truly represents the disulfide connectivities of the native protein.
Determining the cysteine linkages of proteins that contain
closely spaced complex disulfide bonds is a difficult problem. A
number of methods have been employed to address the analytical issues posed by these structures, but they all have limitations. Often, a combination of techniques must be recruited to
completely characterize the disulfide-bonding pattern in such
proteins (31–33). The primary approach used here was the
selective partial reduction of the disulfide bonds in the SMB
domain using Tris(2-carboxyethyl)phosphine (TCEP), followed
by alkylation of the freed cysteines by N-ethylmaleimide
(NEM) under acidic conditions to avoid disulfide scrambling.
The SMB region was cleaved from vitronectin by endoproteinase Glu-C, purified by reverse-phase HPLC, and partially reduced with TCEP under acidic conditions. The partially reduced isoforms were subjected to peptide mapping using mass
spectrometry, and the polypeptide was characterized by 1H
NMR to identify the individual disulfide pairings. Our results
indicate that the domain scaffold with its intricate network of
disulfides is important to orient the single ␣-helix within this
domain (18) properly for binding of ligands including PAI-1 and
uPAR. The SMB domain thus represents a new member of the
cystine-stabilized helix (CSH) family (34).
EXPERIMENTAL PROCEDURES

Materials—NEM and TCEP hydrochloride were from Fluka (Buchs,
Switzerland). Dithiothreitol (DTT) and trifluoroacetic acid were from
Pierce. Iodoacetamide (IAM) and bovine insulin were from Sigma. Guanidine HCl, Tris base, dibasic sodium phosphate, ammonium bicarbonate, ammonium sulfate, acetic acid, phosphoric acid, HPLC grade methanol, and HPLC grade acetonitrile were from Fisher Scientific
(Suwanee, GA). Sequencing grades of endoproteinase Glu-C, trypsin,
and chymotrypsin were from Roche Applied Science.
Endoproteinase Glu-C Digestion of Vitronectin—Native vitronectin
was purified from human blood plasma using a modification of the
method developed by Dahlback and Podack (35) and stored as a precipitate under saturated ammonium sulfate. The ammonium sulfate
slurry of vitronectin was pelleted in 2-ml Eppendorf® tubes in a Beckman Microfuge at 12,000 ⫻ g for 15 min. The pellet was dissolved in 4
M guanidine HCl, 0.02 M iodoacetamide, 0.05 M Na2HPO4, pH 8.0, at a
concentration of 2– 4 mg/ml as determined by absorbance at 280 nm.
The dissolved vitronectin (5–10 mg) was placed in the dark for 1–2 h at
⬃25 °C to block free cysteines. With the free cysteines S-carbamidomethylated, the full-length vitronectin was then transferred to a SlideA-Lyzer® dialysis cassette from Pierce with a 10,000 molecular weight
cut-off, where it was dialyzed against three changes of 1 liter of 4 M

guanidine HCl, 0.1 M Na2HPO4, 0.125 M ammonium bicarbonate, pH
7.4, adjusted with phosphoric acid. Finally, the alkylated vitronectin
was dialyzed exhaustively against 0.1 M Na2HPO4, 0.125 M ammonium
bicarbonate, pH 7.4, adjusted with phosphoric acid. The protein was
removed from the dialysis cassette and the concentration determined by
absorbance at 280 nm. The concentration was adjusted to 1–2 mg/ml
using the same buffer. The protease, endoproteinase Glu-C, was added
to vitronectin at a 1:100 ratio (w/w), and the digest was performed at
37 °C for 24 –30 h.
Purification of Intact and Partially Reduced Forms of the SMB Domain—The peptides generated by the endoproteinase Glu-C digestion
of vitronectin were separated by reverse-phase HPLC using a linear
gradient at 0.5 ml/min from 5 to 55% acetonitrile over 107 min. The
gradient was made by mixing buffer A (0.1% trifluoroacetic acid (w/v) in
water) and buffer B (acetonitrile with 0.085% trifluoroacetic acid (w/v))
in the appropriate proportions on an Agilent 1100 series quaternary
pump HPLC system. A multiple wavelength detector allowed for monitoring of samples at 220 and 280 nm, and a fluorescent detector was
used for monitoring for tryptophan fluorescence (excitation 280 nm,
emission 356 nm). A C-18 Nucleosil column custom packed by Alltech
(5-m particle size, 100 Å pore size, 4.6 ⫻ 150 mm) was used. Column
temperature was maintained at 50 °C. Fractions were collected using a
Gilson FC203 B fraction collector for identification by MALDI-MS.
Additional purification prior to reduction was performed using the
same column and HPLC system with a linear gradient at 0.5 ml/min
from 15 to 45% B over 60 min.
Partial Reduction with TCEP and Alkylation with NEM—Partial
reductions were carried out with an excess of TCEP and the degree of
reduction controlled by stopping the reaction at various times by the
addition of NEM. The times and concentrations were adapted from
Young et al. (36). The HPLC fraction containing the peptide to be
reduced was dried using a Savant Speed-Vac with a dry ice and methanol trap. The dried fractions were dissolved in freshly prepared 0.1%
trifluoroacetic acid (w/v), pH 2.8. TCEP was prepared immediately prior
to use at a concentration of 0.35 M in 0.1% trifluoroacetic acid (w/v), pH
2.8. NEM was also freshly prepared at a concentration of 0.8 M in 0.1%
trifluoroacetic acid (w/v), pH 2.8, and 50% methanol (v/v). Solutions
containing TCEP and NEM were protected from the light at all times.
A 0.05 M Tris base buffer, pH 7.8, was freshly prepared to titrate the
partially reduced samples before alkylation with NEM. Immediately
prior to performing the partial reduction, the amount of Tris buffer
necessary to titrate a given amount of 0.1% trifluoroacetic acid (w/v), pH
2.8, to pH 6.5 was determined empirically. TCEP was added to peptide
to yield a solution with a final concentration of 0.02 M TCEP. Samples
were generally withdrawn at 30, 60, 90, and 120 min and sufficient
NEM was added to the reaction to create a 5:1 molar ratio of NEM to
TCEP. Following the addition of NEM, Tris buffer was added to raise
the pH to 6.5 to facilitate the alkylation reaction. Alkylation was allowed to proceed at ambient temperature (⬃25 °C) for at least 2 h. The
partially reduced and alkylated peptides were then separated by HPLC
as described above and identified by MALDI-MS. Sampling times were
adjusted as necessary to enrich for individual isoforms. Additional
purification of partially reduced and alkylated forms was performed
using a Nucleosil C-18 column and HPLC system with a linear gradient
at 0.5 ml/min from 15 to 45% B over 60 min, as described above.
Digestion of Partially Reduced Forms of the SMB Domain—Partially
reduced forms of the SMB region of vitronectin were digested with
endoproteinase Glu-C, trypsin, and/or chymotrypsin to generate peptides for the determination of individual disulfide bonds. Prior to digestion, partially reduced, alkylated, and HPLC-purified peptides were
completely reduced with DTT, and any free cysteines were S-carbamidomethylated with iodoacetamide. Fractions containing the individual
partially reduced isoforms were dried on the Savant Speed-Vac and
dissolved in 0.1 M ammonium bicarbonate, pH 8.5. Subsequently, DTT
(1 M stock) was added to each peptide at a final concentration of 0.01 M,
and the sample was incubated for 4 h to completely reduce any remaining disulfide bonds in the partially reduced and alkylated peptide.
Iodoacetamide (1 M stock in 0.1 M ammonium bicarbonate, pH 8.5) was
added to the fully reduced peptide to give a final concentration of 0.1 M.
S-Carbamidomethylation with iodoacetamide was performed in the
dark at ambient temperature (⬃25 °C) for 2 h.
Prior to protease digestion, S-carbamidomethylated samples were
desalted using a 300-mg Maxi-Clean® C-18 cartridge from Alltech
according to manufacturer’s instructions, washed on the cartridge with
3% acetonitrile with 0.1% trifluoroacetic acid (w/v), eluted with 50%
acetonitrile with 0.1% trifluoroacetic acid (w/v), dried on the Savant
Speed-Vac, and dissolved in the appropriate digestion buffer. All buffers
for digestion of partially reduced forms were prepared on the day of use,
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and digests were performed at 37 °C for ⬃15 h. Endoproteinase Glu-C
digests were performed in 0.1 M ammonium bicarbonate, pH 7.4. Trypsin and chymotrypsin digests were performed in 0.1 M ammonium
bicarbonate, pH 8.0. All enzymes were added to give a ratio of ⬃50:1
substrate to enzyme (w/w). In the case of dual digests, the peptide was
dried after the first digest using the Savant Speed-Vac, then dissolved
in the appropriate buffer for the second digest, and enzyme was added
in a 50:1 substrate to enzyme (w/w) ratio. After the digestion sequence
was complete, the resulting peptide mixture was dried directly on the
Savant Speed-Vac and dissolved in 0.1% trifluoroacetic acid (w/v). Alternatively, the sample was passed over a 300-mg Maxi-Clean® C-18
cartridge from Alltech, washed on the cartridge with 3% acetonitrile
and 0.1% trifluoroacetic acid (w/v), eluted with 50% acetonitrile and
0.1% trifluoroacetic acid (w/v), dried as described above, and dissolved
in 0.1% trifluoroacetic acid (w/v) for MALDI-MS.
MALDI-MS—MALDI mass spectra were obtained in positive ion
mode using a PerSeptive Biosystems Voyager DE time-of-flight mass
spectrometer, or a Voyager Elite DE reflectron time-of-flight mass
spectrometer, each equipped with a nitrogen laser (Applied Biosystems,
Framingham, MA). Spectra from the Voyager DE instrument were
obtained in linear mode with ⫹20 kV total accelerating voltage, ⫹18.8
kV applied to the grid, ⫹10 V applied to the guide wire, and a 110-ns
acceleration delay. Spectra from the Voyager Elite DE instrument were
obtained in linear mode with ⫹25 kV total accelerating voltage, ⫹23 kV
applied to the grid, ⫹37.5 V applied to the guide wire, and a 100-ns
acceleration delay. Spectra are averages of up to 256 individual laser
pulses, obtained from several locations on each sample spot. Sample
aliquots were applied to a pre-spotted thin-layer matrix, prepared by
applying 0.5-l portions of 5 g/liter nitrocellulose (Immobilon NC Pure,
Millipore, Bedford MA), 20 g/liter ␣-cyano-4-hydroxycinnamic acid (Aldrich; re-crystallized from ethanol before use) in 1:1 isopropyl alcohol:
acetone to the sample plate and allowed to dry (37). External calibration
of the m/z axis was performed using gramicidin S and bovine insulin.
Expected masses to compare with the observed MALDI-MS results
were calculated using Protein Prospector (38).
Electrospray MS—Analysis was also performed by electrospray quadrupole ion trap mass spectrometry (LCQ Deca, ThermoFinnigan, San
Jose, CA). Protease digestion samples that were purified by HPLC were
desalted using a C-18 ZipTip (Millipore, Bedford, MA), and the peptides
were eluted in 10 l of 50:50 acetonitrile:water. A 100-l volume of
48:48:2 acetonitrile:water:acetic acid was added to the desalted sample.
The mixture was then infused directly into the electrospray source of
the mass spectrometer. The ⫹5 charge state ion of the 1–55 digest
fragment, at m/z 1257.3, was isolated using a 5 m/z isolation width and
subjected to collision-induced dissociation to produce a tandem mass
spectrum. Charge state deconvolution produced a plot with abscissa
units of mass (Da).
NMR Spectroscopy—A sample of the SMB domain (residues 1–51 of
vitronectin) was prepared for NMR measurements by cyanogen bromide digestion and HPLC purification, as described (18). NMR spectra
were collected using ⬃90 M SMB in a 500-l sample volume in both
D2O and H2O containing 10% D2O at pH 4.4 and 298 K. All NMR
experiments were performed on a 600 MHz Varian INOVA instrument
equipped with a single gradient axis and a triple resonance probe for
the observation of proton, carbon, and nitrogen nuclei. Two-dimensional
NMR data were acquired in phase-sensitive mode using the StatesHaberkorn method for quadrature detection in the indirect dimension
(39). Spectra of SMB in H2O were recorded by using WET (40, 41) or
WATERGATE sequences (42) for water suppression. Two-dimensional
homonuclear NOESY (43) spectra were recorded with mixing times of
150, 200, and 250 ms. TOCSY spectra (44) were recorded using the
DIPSI (decoupling in presence of scalar interaction) spin-lock sequence
with a 8-kHz radio frequency field and mixing times of 15, 30, 60, and
80 ms. Typically, spectra were acquired with 256 t1 increments, 2048
data points, a relaxation delay of 1 s, and a spectral width of 8500 Hz.
For DQF-COSY spectra (45), 512 t1 increments were acquired. Spectra
were recorded with 64 –96 scans per increment for NOESY, 24 – 80
scans per increment for TOCSY, and 56 scans per increment for DQFCOSY. In all NOESY and TOCSY spectra, the data were multiplied by
a 60 –90° phase shifted sin2 window function in both dimensions before
Fourier transformation.
NMR Data Analysis—NMR data were processed with Felix 2000 and
SPARKY (T. D. Goddard and D. G. Kneller, The University of California, San Diego) software operating on a Silicon Graphics Indigo 2 work
station or on a Silicon Graphics Origin 300 server. Cross-peak intensities observed in NOE experiments were divided into four categories as
strong, medium, weak, and very weak. These intensities were converted
into distance restraints as follows: strong, 1.8 –2.7 Å; medium, 1.8 –3.4
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Å; weak, 1.8 – 4.5 Å, and very weak 1.8 – 6.0 Å. An additional 1.0 Å was
added to upper limits involving methyl protons. Similarly, an additional
0.5 Å for methylene protons and 2.3 Å for degenerate H␦ and H⑀ protons
of tyrosines and phenylalanines were added to upper limits. Also, 0.2 Å
was added to the upper limits of NOEs involving amide protons. Coupling constants were extracted from the DQF-COSY spectra. Backbone
⌽ angles were restrained to ⫺120 ⫾ 50° for 3JHNH␣ ⫽ 8 –9 Hz, and
⫺120 ⫾ 40° for 3JHNH␣ ⬎ 9Hz. A restraint of ⫺100 ⫾ 80° was also
applied to the ⌽ angle for residues that show stronger NHi-H␣i-1 NOE
than the intraresidue NH-H␣ NOE (46). A total of 329 NOE restraints
and 18 ⌽ restraints were used in structure determination. All calculations were carried out using the AMBER force field interfaced with
DISCOVER (Accelerys, San Diego, CA) on an Origin300 work station.
Random structures were generated by subjecting the peptide to an
initial 10,000-step minimization at 298 K. The temperature was then
raised gradually to 1,000 K during a 1,000-step dynamics simulation.
The peptide was subjected to minimization and a 10-ps dynamics run at
1,000 K. The NMR-derived restraints were then imposed on the peptide
and the peptide was slowly annealed to 298 K in a 100-ps trajectory.
Finally, the structures were subjected to further minimization at 298 K.
The force constant for the distance restraints was 100 kcal/mol Å⫺2 and
the dielectric constant was 4.
RESULTS

Endoproteinase Glu-C Digestion of Vitronectin and Isolation
of the N-terminal Peptide—Determination of the disulfidebonding pattern of the SMB domain of vitronectin began with
isolation by protease digestion and reverse-phase HPLC. The
first step in isolating the SMB domain was digesting full-length
vitronectin with endoproteinase Glu-C. Vitronectin contains a
total of 14 cysteine residues, arranged in six disulfide bonds
with the remaining two free sulfhydryls occupying buried positions (47). Four of the six disulfides are found within the first
39 amino acids of the protein in the SMB domain, whereas the
other two have been assigned as Cys137:Cys161 and Cys274:
Cys453 (16). The free sulfhydryls are at positions 196 and 411
(16). Prior to digestion with endoproteinase Glu-C, these two
free cysteines were carboxyamidomethylated with iodoacetamide to avoid any free thiols that could promote disulfide
rearrangements. The carboxyamidomethylated vitronectin was
then digested with endoproteinase Glu-C and the resulting
peptides analyzed by reverse-phase HPLC (Fig. 1A). The key to
generating the optimal separation during HPLC analysis and
purification of the N-terminal domain was the use of a small
pore (100 Å) stationary phase. The size exclusion properties of
the small pore matrix provided additional separation that was
necessary to purify the N terminus apart from other peptides
and full-length vitronectin.
Preparative amounts of the digest were injected (1–1.5 mg/
injection) and purified on the same small pore reverse-phase
matrix. The resulting fractions were analyzed by MALDI-MS.
A peak eluting at ⬃47– 48 min was identified by mass as the
fully oxidized 1– 47-amino acid N-terminal fragment of
vitronectin (Fig. 1A). The expected average mass-to-charge ratio (m/z) was 5332.9 ([M ⫹ H]⫹, isotopically averaged) and the
observed m/z was 5336.1. The peak eluting at ⬃53–54 min was
identified by mass spectrometry as the fully oxidized 1–55
amino acid N-terminal fragment of vitronectin (Fig. 1A). The
expected m/z was 6281.9 ([M ⫹ H]⫹, isotopically averaged) and
the observed m/z was 6284.2. Identity of these peptides also
was confirmed by Edman sequencing (data not shown). The two
N-terminal fragments, vitronectin 1– 47 and vitronectin 1–55,
were dried and re-purified by reverse-phase HPLC prior to
partial reduction. The sample comprising residues 1–55, shown
in Fig. 1B following purification and re-chromatography by
HPLC to evaluate purity, was used for the remainder of the
analyses on disulfide bonds described in this work. Fig. 1C
shows the MALDI-MS spectrum of this sample.
Fig. 1D shows an experiment performed on this sample by
electrospray quadrupole ion trap MS using a Finnigan LCQ
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FIG. 1. Purification and MALDI-MS analysis of the N-terminal SMB domain produced from endoproteinase Glu-C digestion. A
shows a preparative injection of the endoproteinase Glu-C digest of native vitronectin with N-terminal peptides, 1– 47 and 1–55, indicated (arrows).
Vitronectin was S-carbamidomethylated with iodoacetamide to block free cysteines and digested with endoproteinase Glu-C. The resulting
peptides were separated by reverse-phase HPLC on a C-18 column as described under “Experimental Procedures,” and individual peaks were
collected for further analysis. B shows the reverse-phase HPLC profile of vitronectin 1–55 re-purified from the initial HPLC separation (A) of the
endoproteinase Glu-C digest containing the SMB domain of vitronectin. C shows the MALDI-MS of the reverse-phase purified vitronectin 1–55,
with an observed average mass of 6284.2. The spectra were smoothed with a 19-point Savitsky-Golay filter. D shows an electrospray MS/MS
analysis on the purified vitronectin 1–55. From multiple charge states in the mass spectrum (not shown), the average mass was measured as
6281.2, in agreement with the MALDI-MS (C) and the expected mass of 6280.9. The ⫹5 charge-state ion at m/z 1257.3 was isolated using a 5 m/z
isolation width, and subjected to collision-induced dissociation. The masses of fragment ions are given, along with the amino acid of molecular mass
that corresponds to the difference in mass between adjacent species.

Deca instrument. From multiple charge states, the average
mass of the peptide representing the SMB region (residues
1–55 with 4 disulfides) was measured as 6281.2, in excellent
agreement with the calculated value of 6280.9 for the peptide.
Modern MS technology allows for isolation of a peak of interest
in the electrospray spectrum to confirm the peptide by sequence tag identification. The ⫹5 charge state ion at m/z
1257.3 was isolated using a 5 m/z isolation width, subjected to
collision-induced dissociation, and the resulting MS/MS (or
tandem MS) spectrum was obtained (Fig. 1D). The sequence
tag derived from the spectrum, corresponding to species differing in length by a single amino acid residue, agrees with the
known vitronectin sequence, thus confirming that the m/z
1257.3 parent ion is the ⫹5 charge state of the partial digest
fragment containing residues 1–55.
Partial Reduction with TCEP and Alkylation of Free Cysteines with N-Ethylmaleimide—The second step in determining
the disulfide bonding structure of the N-terminal domain of
vitronectin was the partial reduction and alkylation of the
liberated free thiols under acidic conditions. TCEP, the reducing agent, and NEM, the primary alkylating agent, were specifically chosen because the reactions may be performed under
acidic conditions to avoid disulfide scrambling. The purified
N-terminal 1–55 fragment of vitronectin was dried and dissolved in 0.1% trifluoroacetic acid, pH 2.8. The solution was

adjusted to a final concentration of 0.02 M TCEP, and samples
were withdrawn every 30 min over a period of 120 min to
capture all of the possible reaction products. Based upon bovine
insulin injected as a standard on the HPLC for comparison to
the 1–55 fragment at 220 nm prior to partial reduction, the
average concentration of the N-terminal peptide in the reaction
mixture was estimated to be ⬃8 M. The reduction rate of the
peptide at this concentration and pH in the presence of 0.02 M
TCEP was reproducible. Higher pH and/or higher concentrations of TCEP resulted in unacceptably fast reaction times,
making it difficult to capture the single and doubly reduced
reaction products.
The partially reduced samples were alkylated upon addition
of NEM to a final concentration of 0.1 M NEM; sufficient Tris
base was added to bring the pH to 6.5 to facilitate the alkylation reaction with NEM, which effectively stops further reduction by TCEP. The 30- and 60-min samples were analyzed by
MALDI-MS to determine the partial reduction products (Fig.
2). All five possible reduction products ranging from fully oxidized to fully reduced were observed, confirming that the N
terminus of native vitronectin contains four cystines that can
be selectively reduced over time. Fig. 3 is a schematic that
depicts this strategy of partial reduction and NEM blocking,
with the three reduction products of interest for further analysis, the SMB domain corresponding to one, two, or three
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FIG. 2. MALDI-MS analysis of the partial reduction and alkylation of vitronectin 1–55. Vitronectin 1–55 was partially reduced with
TCEP at pH 2.8 followed by alkylation with NEM at pH 6.5. A shows the progress of the reduction and alkylation after 30 min. The mass increases
by 252 Da with the reduction and alkylation of each disulfide bond, with three open bonds clearly shown at 30 min. B shows the progress at 60
min where all of the isoforms are present including the fully reduced and alkylated form.

disulfides open and alkylated (SMB1O, SMB2O, and SMB3O,
respectively). These reduced and alkylated peptides generated
during the partial reduction were purified by reverse-phase
HPLC (Fig. 4A) and the resulting fractions analyzed by
MALDI-MS. Small shoulders observed on the HPLC peaks
(Fig. 4A) from the partial reduction were confirmed by
MALDI-MS to be isoforms reflecting varying amounts of alkylation with NEM. Selected fractions containing the individual reaction products from the partial reduction of the SMB

domain corresponding to one, two, or three disulfides open and
alkylated (SMB1O, SMB2O, and SMB3O) were re-purified by
HPLC (Fig. 4, B–D) and carried forward for further analysis to
determine individual disulfide pairs.
Protease Digestion and Analysis of Alkylated Partial Reduction Products—The strategy for determining the identity of the
liberated sulfhydryls and remaining disulfides in the partially
reduced and alkylated forms of vitronectin 1–55 is presented in
the schemes outlined in Figs. 5–7. Two approaches were used.
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FIG. 3. Strategy for partial reduction of SMB, followed by blocking of freed cysteines with NEM. Shown schematically are the starting
material, fully oxidized SMB, and partially reduced species that have either one, two, or three cystine bonds opened. NEM was used to block the
freed cysteines that are liberated in each of these species. The partially reduced, blocked intermediates that were analyzed further in this work
are labeled as SMB1O, SMB2O, and SMB3O for the partially reduced and NEM-blocked species with either 1, 2, or 3 cystines opened with TCEP,
respectively. Gray circles represent cysteines in a disulfide linkage, aqua circles represent TCEP-reduced and NEM-blocked cysteines, and red lines
represent disulfide bridges in the SMB domain.

In some cases, the samples were digested directly and analyzed
by MALDI-MS. Alternatively, the partially reduced and NEMblocked samples were treated further with DTT to achieve
complete reduction, and alkylation with IAM differentially
tagged the residues that still existed as cystines after TCEP
treatment. Subsequent enzymatic digestion and mass analysis
was then pursued, and the presence of NEM or CAM at individual sites was used to determine which cysteine residues
were oxidized and reduced in the samples with one cystine, two
cystines, or three cystines reduced by TCEP (denoted SMB1O,
SMB2O, and SMB3O in Figs. 3–7).
First, the isoform of the SMB domain that was partially
reduced leaving three disulfides intact and one disulfide pair
reduced and alkylated with NEM (SMB1O, Fig. 5) was digested
directly with trypsin, and the peptides were analyzed by
MALDI-MS (Table I, Supplemental Materials Fig. 1). A peptide
product was identified at m/z of 2063.4. This corresponds to the
predicted m/z of 2061.3 for two peptides linked through a Cys5:
Cys9 disulfide bond (SMB1O-T1/2 in Fig. 5). Specifically, this
product corresponds to vitronectin residues 1– 6 (DQESCK)
disulfide bonded to vitronectin residues 7–18 (GRCTEGFNVDKK). This disulfide bond was the first identified in our
analysis, and its presence was confirmed repeatedly during the
course of this work (see Supplemental Materials Table I).
A sample of the SMB1O form of the domain having a single
pair of cysteines alkylated with NEM was fully reduced with
DTT, and the newly released cysteines were carboxyamidomethylated with IAM, as outlined in Fig. 5. The resulting peptide
was then digested with chymotrypsin and analyzed by
MALDI-MS (Supplemental Materials Figs. 2 and 3). Three
peptide products were identified (Table I). A peak of m/z 2964.6
was observed that corresponds to the expected m/z of 2965.3 for
residues 1–24 with all four cysteines (Cys5, Cys9, Cys19, and
Cys21) carboxyamidomethylated (peptide SMB1O-Ch1, Fig. 5).

The presence of the CAM tag indicates that all of these cysteines were disulfide bonded in the original SMB1O peptide
generated by TCEP and NEM treatment. This is consistent
with the initial observation of the Cys5:Cys9 bond assignment.
Second, a peptide with an observed m/z of 1576.1 was also
seen in the spectrum of this digest. This agrees with the expected m/z, 1575.7, of a peptide containing residues 25–35 in
which two of the cysteines were carboxyamidomethylated and
one was alkylated with maleimide (peptide SMB1O-Ch2, Fig.
5). Also, seen in this reaction is a further cleavage product of
SMB1O-Ch2, a peptide spanning residues 28 –35 with both
cysteines carboxyamidomethylated (peptide SMB1O-Ch3, Fig.
5). This peptide yields an observed m/z of 1096.4, which corresponds to the expected m/z of 1097.2 for this sequence. From
comparison of the results on peptides SMB1O-Ch2 and
SMB1O-Ch3, it is deduced that Cys25 in peptide SMB1O-Ch2
must be the residue alkylated with NEM. Thus, Cys25 was a
half-cystine released during the partial reduction with TCEP
that yielded the SMB1O form. All of the other 6 cysteine residues identified from this analysis were CAM labeled, indicating that these 6 residues remain paired in the initial reduction
to form SMB1O. By the process of elimination, the only remaining cysteine residue, Cys39, should be the other half-cystine
partner for Cys25. Unfortunately, the MALDI-MS spectrum for
this digest did not show the peptide comprising residues 36 –55
in whole or part. Whereas these results, combined with those
for the tryptic digest of the SMB1O form of vitronectin 1–55,
suggest that Cys25:Cys39 forms a disulfide pair, Cys39 alkylated
with NEM was not recovered to confirm this inference.
Definitive evidence for the Cys25:Cys39 assignment was
gained from analysis of the SMB domain that was partially
reduced to yield four free cysteines alkylated with NEM
(SMB2O, Fig. 6). This partial reduction product was fully reduced and alkylated with IAM, so that the cystines remaining
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FIG. 4. Purification of individual
partially
reduced
isoforms
of
vitronectin 1–55. A shows the reversephase HPLC separation of the isoforms of
vitronectin 1–55 created during the partial reduction and alkylation. SMB is the
fully oxidized SMB domain of vitronectin.
As outlined schematically in Fig. 3,
SMB1O is the singly reduced isoform,
shown here in both singly and doubly
alkylated forms. SMB2O is the doubly
reduced isoform that has been fully alkylated. SMB3O is the triply reduced isoform, and SMB4O is the fully reduced
isoform shown here with one free cysteine
as well as the fully alkylated form. A linear gradient was used at 0.5 ml/min from
5 to 55% buffer B over 107 min, as described under “Experimental Procedures.” B–D show the reverse-phase
HPLC profiles of the partially purified
isoforms representing 1, 2, and 3 open
disulfides, respectively. B, the re-purification of SMB1O, which used a gradient
from 15 to 45% B over 50 min at a flow
rate of 0.5 ml/min. C, the re-purification
of SMB2O, which used a gradient from 18
to 45% B over 50 min at a flow rate of 0.5
ml/min. D, the re-purification of SMB3O,
which used a gradient of 20 to 50% B over
50 min at a flow rate of 0.5 ml/ml. Shown
beside panels B–D are schematic figures
depicting SMB1O, SMB2O, and SMB3O,
respectively (see Fig. 3).

after TCEP treatment can be identified with the CAM tag. The
doubly tagged peptide was digested with chymotrypsin, and the
products were analyzed by MALDI-MS (supplemental Fig. 4).
Three peptides of interest were observed (Table I). The first
(SMB2O-Ch1, Fig. 6), with an observed m/z of 1677.4, agrees
with the expected m/z of 1676.9 for a peptide containing residues 36 – 49 with the sole cysteine (Cys39) alkylated by NEM.
The second peptide, SMB2O-Ch2 (Fig. 6) is identified as containing residues 14 –24, with both cysteines tagged with CAM.
Finally, the third m/z observed was 1097.0, which corresponds
to residues 28 –35 with both cysteines tagged with CAM, with
a calculated m/z 1097.2 (SMB2O-Ch3, Fig. 6). Thus, Cys19,
Cys21, Cys31, and Cys32 observed here in the CAM form are,
therefore, disulfide bonded to each other in SMB2O. Cys39 was
observed in peptide SMB2O-Ch1 to be alkylated by NEM, indicating that Cys39 was a half-cystine released during the
partial reduction that disrupted two disulfides. Thus, the combined information derived from all three digests of the partial
reduction products from both the SMB1O and SMB2O isoforms
supports the conclusion that Cys25:Cys39 forms a disulfide pair
and are the first pair released during the partial reduction.

Other data supporting the Cys25:Cys39 and Cys5:Cys9 assignments are summarized in supplemental Table I.
Having confirmed that the first two disulfide bonds disrupted by TCEP treatment are Cys25:Cys39 and Cys5:Cys9,
respectively, the final assignments required discerning the arrangement of two other disulfides among residues Cys19, Cys21,
Cys31, and Cys32. The partially reduced form of the SMB domain that resulted in three reduced disulfides (6 free cysteines)
labeled with NEM after TCEP treatment, and a single remaining disulfide bond, was purified (SMB3O, Fig. 7). The residual
disulfide bond was reduced with DTT and the newly freed
cysteines were carboxyamidomethylated with IAM. This peptide was initially digested with chymotrypsin and analyzed by
MALDI-MS. Two prominent peptides were observed from this
analysis. One, with a m/z of 2648.0, corresponded to the expected core fragment comprising residues 18 –35 with three
cysteines tagged with NEM and only two (from the last disulfide to remain unreduced with TCEP) tagged with CAM, with a
calculated m/z of 2648.9. This data in itself was not definitive,
because there are 5 cysteines within this core peptide and they
cannot be identified without sequencing data. Although it had
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FIG. 5. Strategy for proteolysis and MALDI-MS analysis on
digestion products from SMB1O. This scheme outlines the experimental procedures that were performed to identify free cysteines and
disulfide bridges in the SMB domain with one cystine opened with
TCEP, and the two liberated cysteines blocked with NEM (SMB1O).
This SMB isoform was treated in two ways. In one strategy, the SMB1O
was digested with trypsin, and the digest products were identified by
mass analysis using MALDI-MS. A unique peak was identified that
corresponded to two cleavage fragments connected by a disulfide, denoted as SMB1O-T1/2. In the second approach, the SMB1O fragment
was fully reduced with DTT and the newly liberated cysteines were
blocked with IAM, as described under “Experimental Procedures.” This
fully reduced, and differentially blocked SMB isoform, was then digested with chymotrypsin, and digest products were analyzed by
MALDI-MS. Three fragments were identified, denoted SMB1O-Ch1,
SMB1O-Ch2, and SMB1O-Ch3. Table I lists expected masses and observed masses for all fragments depicted in this scheme.

already been determined that Cys25 was paired with Cys39
(outside this core peptide), the three possible arrangements
between the remaining four cysteine residues are not obvious.
Therefore, the SMB3O sample was digested sequentially
with two enzymes, endoproteinase Glu-C followed by chymotrypsin (Fig. 7). This combination of enzymes is expected to
cleave at positions 22 or 23, intermediate between the Cys19Gln-Cys21 region and the Cys31-Cys32 sequence. Mass identification of each of the two separate fragments (containing Cys19
and Cys21 or Cys31 and Cys32) with both NEM and CAM labels
would indicate that proximal cysteines do not pair and that
disulfides must form in a non-linear fashion. In fact, this result
is observed; each of two peptides, SMB3O-GCh1 and SMB3OGCh2 (Fig. 7, Table I), contained one NEM-modified residue
and one CAM-modified cysteine (supplemental Figs. 5 and 6).

FIG. 6. Strategy for proteolysis and MALDI-MS analysis on
digestion products from SMB2O. This scheme outlines the experimental procedures that were performed to identify free cysteines and
disulfide bridges in the SMB domain with two cystines opened with
TCEP, and the four liberated cysteines blocked with NEM (SMB2O).
This SMB2O fragment was fully reduced with DTT and the newly
liberated cysteines were blocked with IAM, as described under “Experimental Procedures.” This fully reduced, and differentially blocked SMB
isoform, was then digested with chymotrypsin, and digest products
were analyzed by MALDI-MS. Three fragments were identified, denoted SMB2O-Ch1, SMB2O-Ch2, and SMB2O-Ch3. Table I lists expected masses and observed masses for all fragments depicted in this
scheme.

The MALDI-MS data are therefore consistent with Cys19 bonding with either Cys31 or Cys32, and, likewise, Cys21 bonding
with the other between the same two residues (see also supplemental Table I). Thus, the data indicate one of only two
disulfide arrangements in the core region, i.e. a combination of
Cys19:Cys31 and Cys21:Cys32 or a pairing between Cys19:Cys32
and Cys21:Cys31. Although final distinction between these two
possible disulfide assignments was not possible from this approach alone, the analysis ruled out the unlikely possibility
that cysteines Cys31 and Cys32 are in a vicinal disulfide. Such
vicinal arrangements are extremely rare in protein structures
and do not appear in the SMB domain.
NMR Approach to Assign the Disulfides in the Core Region
Spanning Residues 19 –35—As the tactic using peptide mapping and mass spectrometry was in progress, we initiated a
study to determine the three-dimensional structure of the SMB
domain isolated from human plasma vitronectin using 1H
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The disulfide bridge restraints were set for the two alternatives
(48), and both were subjected to simulated annealing separately. Fig. 8 shows the results of these analyses, which clearly
assign the core disulfides as Cys19:Cys31 and Cys21:Cys32. Plotted in Fig. 8 are two arrays that compare sets of simulated
annealing calculations for the two possible arrangements of
disulfide pairs. The results are color coded to represent the
calculated root mean square deviation relating pairs of structures in the matrix. For each set of calculations, the color range
is yellow (0 –2.5 Å), blue (2.5–5 Å), and cyan (⬎5 Å). From this
visual display of the matrix of structures generated, it is obvious that calculations with the second alternative involving
disulfides Cys19:Cys32 and Cys21:Cys31 did not yield acceptable
converged structures. Thus, the disulfide arrangement for the
two cystine linkages in the core of the SMB domain is Cys19:
Cys31 and Cys21:Cys32.
DISCUSSION

FIG. 7. Strategy for proteolysis and MALDI-MS analysis on
digestion products from SMB3O. This scheme outlines the experimental procedures that were performed to identify free cysteines and
disulfide bridges in the SMB domain with three cystines opened by
TCEP, and the six liberated cysteines blocked with NEM (SMB3O).
This SMB3O fragment was fully reduced with DTT and the newly
liberated cysteines were blocked with IAM, as described under “Experimental Procedures.” This fully reduced, and differentially blocked isoform, was then digested with two enzymes, endoproteinase Glu-C and
chymotrypsin, and digest products were analyzed by MALDI-MS. Two
fragments were identified, denoted SMB3O-GCh1 and SMB3O-GCh2.
Table I lists expected masses and observed masses for the fragments
depicted in this scheme.

NMR. The source material for the NMR analysis was the Nterminal 51 amino acids from vitronectin, isolated by cyanogen
bromide cleavage, rather than the 55-residue fragment isolated
by endoproteinase Glu-C digestion that was used for the peptide mapping/MS analyses. Because the four cystines are confined to residues 5–39, the two samples were suitable for parallel studies on the disulfide bonds. The procedure for
determining the overall three-dimensional fold for the SMB
domain was standard, involving sequence assignments for 1H
resonances and two-dimensional NOESY data to assign interactions between protons that occur at medium to long range
and thus dictate the fold of the domain (18). Simulated annealing calculations were used with iterative energy minimizations
to arrive at the final structure (18). Initially the structural
calculations were pursued without any disulfide restraints,
yielding results that were consistently in agreement with the
Cys5:Cys9 and Cys25:Cys39 assignments (18). Thus, an NMR
approach was taken to distinguish the two possibilities for the
final disulfide assignments in the 19 –35 core region.
For this analysis, the two disulfides generated from the
peptide mapping/MS work were imposed to refine the structure
of the SMB domain, and two possible alternatives were then
pursued separately in the structure determination: Cys19:Cys31
and Cys21:Cys32 pairs or Cys19:Cys32 and Cys21:Cys31 pairs.

In the study presented here, we have selectively reduced, in
a stepwise fashion, the native disulfide bonds of the SMB
domain of vitronectin and then alkylated the freed cysteines.
Using peptide mapping, mass spectrometry, and NMR, we
have determined that the disulfide bonds in the SMB domain of
vitronectin are Cys5:Cys9, Cys19:Cys31, Cys21:Cys32, and Cys25:
Cys39. Apart from the first two cysteine residues that form the
Cys5:Cys9 bond, the order of disulfides in this small domain is
reminiscent of the arrangement found in a large number of
proteins that fall into the “cystine knot” motif (22, 24, 26, 49).
That is, the remaining six cysteines are bonded in an “n:n ⫹ 3”
pattern, i.e. the first in the series forms a disulfide with the
fourth (Cys19:Cys31), the second with the fifth (Cys21:Cys32),
and the third with the sixth (Cys25:Cys39). Perhaps the best
recognized members of this cystine knot family are the growth
factor-type cystine knots, which contain six cysteines paired in
a similar pattern to form a “ring” structure through which part
of the peptide chain is threaded in this small domain (22, 50).
Despite this interesting comparison, this analogy with cystine
knots should not be over-interpreted. For one thing, many of
the growth factor-type cystine knots have an extra unpaired
cysteine residue. Also, a major difference between this structure and cystine knots is apparent from the solution structure
of the SMB domain (18), which contains a single ␣-helix as the
only element of secondary structure, whereas cystine knots are
often rich in mini-␤-sheets (22).
Furthermore, the local context and amino acid spacing between cysteine residues is important in directing the overall
fold of a cystine knot. A close inspection of the primary sequence of the cysteine-rich N-terminal portion of vitronectin
reveals that it contains four disulfides within contexts highly
similar to cystine knot proteins (27) (Fig. 9A). However, the
ordering of recognized sequence patterns surrounding individual cysteines along the SMB polypeptide chain differs from
many of the known homologues. For example, key common
patterns in cystine knot proteins are represented in the form of
CXGXC and CXC, where X may be any amino acid other than
Cys. In six-membered and eight-membered cystine knots, such
as observed with the EGF fold (27) or bone morphogenic protein
agonists (24), respectively, these four cysteines occur in a well
defined order and form the ring structure of the classical cystine motif. Typically, the order is C2XGXC3 and C5XC6 with
disulfide pairings of Cys2:Cys5 and Cys3:Cys6 (24) (Fig. 9A).
However, in the SMB domain of vitronectin, the cysteines occur
in the order C1XGXC2 and C3XC4 with disulfide pairings of
Cys1:Cys2, Cys3:Cys6, and Cys4:Cys7 resulting in a pseudo-knot
(51) (Fig. 9B). Thus, this domain assumes a different bonding
pattern from the typical knotted protein and the ring motif is
lacking.
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TABLE I
Assignment of peptides from enzyme digests of the SMB domain by MALDIa

a

MALDI spectra for the assignments in this table are shown in supplementary Figs. 1– 6.
Sequences of peptides from the SMB domain are given, with the corresponding numbers in the amino acid sequence. Cysteines labeled with
CAM (carbamidomethyl) or NEM (N-ethylmaleimide) are shown by subscripts. Boxes in the bottom row indicate that one cysteine in the peptide
is labeled with CAM and the other with NEM, but it is not possible to distinguish these possibilities form MALDI data alone.
c
Nomenclature for identified peptides correlates with the schemes shown in Figs. 5–7.
d
Observed m/z ratios by MALDI are given mean ⫾ range. The number of replicate samples measured is shown in parentheses.
e
Boxes indicate that one cysteine is modified with CAM and the other with NEM, but it is not possible to identify which from MS data alone.
b

FIG. 8. Distinguishing two disulfide pairing possibilities in the core of the SMB domain by NMR measurements and refinement.
Simulated annealing calculations were used to distinguish two possibilities for the disulfide-bonding patterns between Cys19, Cys21, Cys31, and
Cys32. Calculations were performed as described under “Experimental Procedures” using proton assignments, measured NOEs, and the Cys5:Cys9
and Cys25:Cys39 disulfide bonds as restraints. Each calculated structure was compared with all other calculated structures by means of a
two-dimensional array. The resulting grid was color coded to represent the calculated root mean dquare deviation relating pairs of structures in
the matrix. For each set of calculations, the color range is yellow (0 –2.5 Å), blue (2.5–5 Å), and cyan (⬎5 Å). Panel A is a comparison of 61 structures
calculated with Cys19:Cys31 and Cys21:Cys32 disulfides in the core region. Panel B is a comparison of 38 structures with Cys19:Cys32 and Cys21:Cys31
disulfides in the core region.
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FIG. 9. Pattern of disulfides in somatomedin B from human
plasma vitronectin. A schematic of the sequence of the vitronectin
SMB domain with assigned disulfides is shown for comparison with the
typical disulfide pattern for the growth factor type cystine knots (A
(27)). Local sequence motifs that are common between the growth factor
type cystine knots and the SMB domain are color coded, revealing a
different ordering between the two sequences. The assignment of disulfides determined in this work for the SMB domain from human
plasma vitronectin is depicted in B. This assignment of cystines agrees
with the solution structure determined on the native domain from
human plasma vitronectin (18). 1, the arrangement of disulfides originally proposed for a recombinant form of the SMB domain by Kamikubo
et al. (28) is shown in C. This group has recently published work that
proposes that at least 4 other disulfide patterns for rSMB are compatible with their NMR structure (19). 2, the disulfide pattern observed by
Zhou and co-workers (17) for a recombinant SMB in a co-crystal with
PAI-1 is shown in D.

In this way, we were able to show that the SMB domain of
vitronectin does not form a classical disulfide knot. Nevertheless, it does possess features with a high degree of similarity to
cystine knot proteins. Most prominent among these is a loop
formed by the disulfide pairing between Cys25 and Cys39, which
is reminiscent of structures classified as cystine-stabilized
␣-helices (CSH motifs). Such structures are known to function
in extracellular ligand interactions (27). Interestingly, this loop
contains residues that have been shown to be involved in binding PAI-1 (13) and uPAR (15), and the region from residues 26
to 30 forms the sole ␣-helix in this small domain (17, 18). This
ligand-binding loop has a calculated pI of 3.7 and is oriented
toward the solvent by the tightly structured core formed by the
Cys19:Cys31 and Cys21:Cys32 disulfide pairings. On the far N
terminus is a small positively charged loop formed by the
Cys5:Cys9 disulfide bond, suggesting that the SMB domain of
vitronectin has a small positively charged tail opposite a large
negatively charged ligand-binding nose.
This sequence of disulfide pairings is in agreement with the
solution structure from NMR determined recently by our laboratory (18) (Fig. 9B). These results are, however, at odds with
previously published results for recombinant counterparts of
the SMB domain of vitronectin (17, 28). Kamikubo et al. (28)
employed similar partial reduction methods with TCEP to discern the disulfide connectivities of a form of the SMB domain
isolated from a fusion protein expressed in E. coli. They identified Cys5:Cys9, Cys19:Cys21, Cys25:Cys31, and Cys32:Cys39 as
the cystine pattern in their recombinant protein (rSMB) (28)
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(Fig. 9C). The underlying assumption made by Kamikubo et al.
(28) was that rSMB contained the native disulfide framework
of vitronectin because it was functionally active in their in vitro
assays and it had comparable PAI-1 binding activity to multimeric vitronectin. Also, mutagenesis of half-cystines within
two of their proposed disulfides resulted in a complete loss of
biological activity. However, work on other proteins displaying
a cystine knot motif has shown that biological activity may
often be misleading, in that forms with one or more disulfides
missing or disrupted can maintain full biological activity (30,
52–54).
Whereas not previously observed as a native structure
among proteins harboring the familiar cystine knot motif, the
structure proposed by Kamikubo et al. in 2002 (28) and further
elaborated upon in 2004 (19) is familiar from the literature on
cystine knots where it has been characterized as a highly stable
folding intermediate (55). In a study describing non-native
disulfide bonding patterns in oxidative folding intermediates of
the Amaranthus ␣-amylase inhibitor, a member of the inhibitory cystine knot family, a major folding intermediate is identified as a peptide structure with a “linear uncrossed pattern”
(55). The NMR structure for the major folding intermediate of
the ␣-amylase inhibitor showed that it appears as compact as
the native knotted protein, presumably because of conformational restraints imposed by a vicinal disulfide bridge. Other
disulfide intermediates are short-lived compared with the major folding intermediate with its linear bonding pattern (56).
Another example of a linear arrangement of disulfides observed
en route to the correct final fold comes from work by Wilken
and Bedows (57) on chorionic gonadotropin ␤-subunit. In this
work, a transient disulfide forms in vivo between Cys3 and Cys4
(nearest neighbors, although not vicinal, in the sequence). This
disulfide is rearranged to form a typical Cys3:Cys6 linkage in
the secreted, mature form of the protein. Thus, it appears that
the linear disulfide assignments reported by Kamikubo et al.
(28) on rSMB represent a stable folding intermediate rather
than the native arrangement of cystines.
The first report of a three-dimensional structure for the SMB
domain by Zhou et al. (17) also used a recombinant SMB domain that was co-crystallized with the active recombinant mutant PAI-1. The disulfide-bonding pattern observed in their
study was Cys5:Cys21, Cys9:Cys39, Cys19:Cys32, and Cys25:
Cys31 (Fig. 9D). This matches neither our pattern for native
SMB (Fig. 9B), nor the original linear pattern reported for a
recombinant SMB by Kamikubo et al. (28) (Fig. 9C). More
recently Kamikubo et al. (19) have determined a three-dimensional structure for their recombinant SMB and have suggested that there are numerous disulfide patterns that are
consistent with their fold. We emphasize by contrast the
unique assignment of disulfides for the SMB domain isolated in
our work from human plasma vitronectin, for which we have no
evidence for heterogeneity or multiple disulfide arrangements.
Although the solution structure from our NMR work (18) and
the structures on the recombinant SMB domains (17, 19) differ
in overall fold, they are similar in one critical feature, the
presence of the single ␣-helix that houses PAI-1- and uPARbinding residues (17, 28). Despite different disulfide scaffolds,
both structures form what appears to be a conserved helix
reminiscent of the CSH motif observed in traditional cystine
knot proteins. This curious result may stem from the demonstrated malleability of CSH structures to accommodate cysteine substitutions, yet retain biological activity (29, 30). Nevertheless, the different disulfide pairs in the recombinant forms
of the SMB domain do not represent the proper arrangement in
the physiological scenario. In similar types of knotted structures, folding studies have shown that the energetic differences
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between native and non-native folds is not large (55, 56, 58). In
a study on disulfides in vascular endothelial growth factor, it
was observed that removal of disulfides leads to folding anomalies and a lower Tm for unfolding, although the overall thermodynamic stability for the various mutants was comparable
(59). Also, other work has suggested that a native disulfide
arrangement may be more significant for the biological half-life
and proper secretion of the polypeptide, as opposed to activity
(60). In this regard, comparisons among several disulfide arrangements in gonadotropin ␣-subunit showed that, despite
the fact that all were nominally active in a bioassay, only the
native disulfide cross-links lend normal kinetics of secretion
from cells (53). Such studies suggest that the native fold is
more kinetically favored, regardless of small energetic differences between native and misfolded disulfide knots.
The SMB domain of vitronectin possesses sequence homologies that are tantalizing in their similarity to the cystine knot
motif. In comparison to classic cystine knots, it appears that a
permutation in the arrangement of sequence microdomains
surrounding the cysteines in the SMB domain nevertheless
results in a structure that mimics these models in terms of
folding and stability. Adopting the fold of a pseudo-knot, the
SMB domain of vitronectin shares common attributes with true
cystine knot proteins. Whereas studies on recombinant SMB
domains have contributed valuable information regarding
some features that are required for ligand binding to vitronectin, the SMB domain isolated from native monomeric vitronectin, having disulfide bonds between Cys5:Cys9, Cys19:Cys31,
Cys21:Cys32, and Cys25:Cys39, represents the biologically relevant form of the domain with a CSH motif.
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